Company intelligence / Profile preview

Lexigen

Vienna, Vienna, Austria

Ownership: Private
Development stage: Other

Overview

Lexogen provides innovative, proprietary RNA sequencing technologies and NGS services used by academic and industry partners for transcriptomics research, target ID, and biomarker discovery in disease states including cancer; recently launched several kit technologies and expanded single-cell RNA-seq capabilities.

Modalities: NGS ServicesRNA AnalysisRNA Sequencing KitsSoftware
Industry: Non-Drug Biotech

Partnerships

Not publicly specified; works with pharma, biotech, and academic clients through service agreements

Beyond the preview

Go deeper on Lexigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lexigen.

Explore the full profile